MTA2 sensitizes gastric cancer cells to PARP inhibition by induction of DNA replication stress

Poly (ADP-ribose) polymerase (PARP) inhibitor olaparib selectively kills cancer cells with BRCA-deficiency and is approved for BRCA-mutated breast, ovarian and pancreatic cancers by FDA. However, phase III study of olaparib failed to show a significant improvement in overall survival in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Jinwen, Zhang, Xiaofeng, Li, Jin'e, Huang, Wenwen, Wang, Yini, Wang, Yi, Qin, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313750/
https://www.ncbi.nlm.nih.gov/pubmed/34280886
http://dx.doi.org/10.1016/j.tranon.2021.101167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313750/
https://www.ncbi.nlm.nih.gov/pubmed/34280886
http://dx.doi.org/10.1016/j.tranon.2021.101167

Ejemplares similares